Skip to main content

External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole.

Publication ,  Journal Article
Wu, YSS; Cohen-Wolkowiez, M; Hornik, CP; Gerhart, JG; Autmizguine, J; Cobbaert, M; Gonzalez, D ...
Published in: Antimicrob Agents Chemother
June 17, 2021

The antibiotic combination trimethoprim (TMP)-sulfamethoxazole (SMX) has a broad spectrum of activity and is used for the treatment of numerous infections, but pediatric pharmacokinetic (PK) data are limited. We previously published population PK (popPK) models of oral TMP-SMX in pediatric patients based on sparse opportunistically collected data (POPS study) (J. Autmizguine, C. Melloni, C. P. Hornik, S. Dallefeld, et al., Antimicrob Agents Chemother 62:e01813-17, 2017, https://doi.org/10.1128/AAC.01813-17). We performed a separate PK study of oral TMP-SMX in infants and children with more-traditional PK sample collection and independently developed new popPK models of TMP-SMX using this external data set. The POPS data set and the external data set were each used to evaluate both popPK models. The external TMP model had a model and error structure identical to those of the POPS TMP model, with typical values for PK parameters within 20%. The external SMX model did not identify the covariates in the POPS SMX model as significant. The external popPK models predicted higher exposures to TMP (median overprediction of 0.13 mg/liter for the POPS data set and 0.061 mg/liter for the external data set) and SMX (median overprediction of 1.7 mg/liter and 0.90 mg/liter) than the POPS TMP (median underprediction of 0.016 mg/liter and 0.39 mg/liter) and SMX (median underprediction of 1.2 mg/liter and 14 mg/liter) models. Nonetheless, both models supported TMP-SMX dose increases in infants and young children for resistant pathogens with a MIC of 1 mg/liter, although the required dose increase based on the external model was lower. (The POPS and external studies have been registered at ClinicalTrials.gov under registration no. NCT01431326 and NCT02475876, respectively.).

Duke Scholars

Published In

Antimicrob Agents Chemother

DOI

EISSN

1098-6596

Publication Date

June 17, 2021

Volume

65

Issue

7

Start / End Page

e0214920

Location

United States

Related Subject Headings

  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Microbiology
  • Infant
  • Humans
  • Child, Preschool
  • Child
  • Anti-Bacterial Agents
  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology
  • 3107 Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wu, Y. S. S., Cohen-Wolkowiez, M., Hornik, C. P., Gerhart, J. G., Autmizguine, J., Cobbaert, M., … Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. (2021). External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole. Antimicrob Agents Chemother, 65(7), e0214920. https://doi.org/10.1128/AAC.02149-20
Wu, Yi Shuan S., Michael Cohen-Wolkowiez, Christoph P. Hornik, Jacqueline G. Gerhart, Julie Autmizguine, Marjan Cobbaert, Daniel Gonzalez, and Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. “External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole.Antimicrob Agents Chemother 65, no. 7 (June 17, 2021): e0214920. https://doi.org/10.1128/AAC.02149-20.
Wu YSS, Cohen-Wolkowiez M, Hornik CP, Gerhart JG, Autmizguine J, Cobbaert M, et al. External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0214920.
Wu, Yi Shuan S., et al. “External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole.Antimicrob Agents Chemother, vol. 65, no. 7, June 2021, p. e0214920. Pubmed, doi:10.1128/AAC.02149-20.
Wu YSS, Cohen-Wolkowiez M, Hornik CP, Gerhart JG, Autmizguine J, Cobbaert M, Gonzalez D, Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0214920.

Published In

Antimicrob Agents Chemother

DOI

EISSN

1098-6596

Publication Date

June 17, 2021

Volume

65

Issue

7

Start / End Page

e0214920

Location

United States

Related Subject Headings

  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Microbiology
  • Infant
  • Humans
  • Child, Preschool
  • Child
  • Anti-Bacterial Agents
  • 3214 Pharmacology and pharmaceutical sciences
  • 3207 Medical microbiology
  • 3107 Microbiology